Chinese Biopharmaceutical Company: Clinical trial application for TQF3250 Capsules accepted by NMPA.

China Biopharmaceuticals announced that the clinical trial application for TQF3250 capsules, a GLP-1 receptor agonist, has been accepted by the NMPA. This drug is mainly metabolized by the CYP3A enzyme, with low risk of drug interactions. Currently, there is only one orally available GLP-1RA approved for market. The group will accelerate the clinical development of TQF3250 to provide more convenient and effective treatment options for type 2 diabetes patients.